全球乳癌市场规模、份额和成长分析：按癌症和配销通路- 行业预测（2023-2030）

Global Breast Cancer Market Size, Share, Growth Analysis, By Cancer(Hormone Receptor-positive (HR+) and HER2-positive (HER2+)), By Distribution Channel(hospital pharmacies, retail pharmacies) - Industry Forecast 2023-2030

出版日期: 2023年10月12日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2021年全球乳癌市场规模为288.8亿美元，从2022年的318.9亿美元成长到2030年的705.3亿美元，年复合成长率预计将成长10.43%。

全球乳癌发生率不断上升推动了该市场的发展。生活型态的改变、荷尔蒙失衡、遗传倾向和高龄化因素导致乳癌病例增加。患者数量的不断增加需要开发有效且创新的治疗方案和诊断工具。技术进步在市场成长中发挥重要作用。分子成像、基因检测、液体活检等新诊断技术能够实现乳癌的早期发现和准确诊断。同样，包括标靶治疗、免疫疗法和精准治疗方法在内的治疗进展正在改善患者的治疗结果和存活率。这些进步正在推动市场对创新产品和治疗方法的需求。此外，公众对乳癌的认识不断提高以及早期检测的重要性，导致人们更多地参与筛检计划和定期检查。世界各地的政府和医疗机构正在进行宣传活动，以促进早期发现，从而导致对筛检和诊断的需求增加。儘管成长前景良好，但市场也面临一些挑战。主要挑战之一是乳癌治疗的高成本，包括手术、化疗、放射线治疗和标靶治疗。患者和卫生系统的经济负担可能会限制获得最佳治疗方案，特别是在资源有限的环境中。

全球乳癌市场动态

全球乳癌市场的驱动因素

提高认识和早期发现

人们对乳癌的认识和早期检测的重要性不断提高，导致人们更多地参与筛检计划和定期检查。政府配合措施、意识提升活动和支持组织在促进早期检测、促进市场成长方面发挥关键作用。

医疗支出增加

医疗保健支出的增加，特别是在已开发国家，正在支持市场的成长。研究与开发、基础设施开发和先进治疗方法方面的投资正在对市场产生积极影响。

全球乳癌市场的抑制因素

个人化医疗的挑战

乳癌是一种异质性疾病，有不同的亚型和不同的治疗反应。开发个体化治疗方法并为每位患者确定最合适的治疗方法既困难又耗时，限制了精准医学的普及。

医疗保健差异和获得治疗的机会

获得医疗保健方面的差异，特别是在低收入地区和服务不足的人群中，是主要障碍。筛检计划、诊断设施、专业治疗和支持性护理服务的取得机会有限，阻碍了及时诊断和最佳治疗，影响了市场成长。

全球乳癌趋势

标靶治疗的兴起：标靶治疗透过选择性地针对癌细胞内的特定分子异常，彻底改变了乳癌的治疗。 HER2标靶治疗，例如单株抗体和酪胺酸激酶抑制剂，显着改善了HER2阳性乳癌的治疗结果。此外，专注于其他分子标靶的新标靶治疗，如 PI3K 抑制剂和 CDK4/6 抑制剂，在各种乳癌亚型中显示出前景。

以病人为中心的方法：市场越来越关注以病人为中心的照护。病患权益倡导者、医疗保健提供者和製药公司正在共同努力满足乳癌患者的整体需求。这包括提供支持性护理服务、生存计划和社会心理支持，以改善患者整个就诊过程中的生活品质。

本报告针对全球乳癌市场进行研究和分析，提供市场动态与前景、細項分析、公司简介等。

Pfizer Inc. - US
Novartis AG - Switzerland
Roche Holding AG - Switzerland
AstraZeneca PLC - UK
Johnson & Johnson - US
Merck & Co., Inc. - US
Bristol Myers Squibb Company - US
Eli Lilly and Company - US
Sanofi - France
AbbVie Inc. - US
Daiichi Sankyo Company, Limited - Japan
Amgen Inc. - US
Genentech, Inc. - US
Takeda Pharmaceutical Company Limited - Japan
Eisai Co., Ltd. - Japan
Mylan NV - US
Celgene Corporation - US
Astellas Pharma Inc. - Japan
Teva Pharmaceutical Industries Ltd. - Israel
Hologic, Inc. - US

简介目录

Product Code: SQMIG35D2109

Global Breast Cancer Market size was valued at USD 28.88 Billion in 2021 and is poised to grow from USD 31.89 Billion in 2022 to USD 70.53 Billion by 2030, at a CAGR of 10.43% during the forecast period (2023-2030).

The breast cancer market is driven by the increasing incidence of breast cancer cases globally. Factors such as lifestyle changes, hormonal imbalances, genetic predisposition, and the aging population contribute to the rising number of breast cancer cases. This growing patient population necessitates the development of effective and innovative treatment options and diagnostic tools. Technological advancements play a crucial role in the growth of the breast cancer market. Novel diagnostic techniques, such as molecular imaging, genetic testing, and liquid biopsies, enable early detection and accurate diagnosis of breast cancer. Similarly, advancements in treatment modalities, including targeted therapies, immunotherapies, and precision medicine, have improved patient outcomes and survival rates. These advancements drive the demand for innovative products and therapies in the market. Moreover, the increasing awareness of breast cancer and the importance of early detection among the general population have led to greater participation in screening programs and routine check-ups. Governments and healthcare organizations worldwide have implemented awareness campaigns to promote early detection, resulting in increased demand for screening and diagnostic procedures. Despite the growth prospects, the breast cancer market also faces several challenges. One significant challenge is the high cost associated with breast cancer treatment, including surgery, chemotherapy, radiation therapy, and targeted therapies. The financial burden on patients and healthcare systems can limit access to optimal treatment options, especially in resource-constrained settings.

Top-down and bottom-up approaches were used to estimate and validate the size of the global Breast Cancer Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Breast Cancer Market Segmental Analysis

The global breast cancer market is segmented on the basis of cancer, distribution channel, and region. By cancer, the market is segmented into Hormone Receptor-positive (HR+) and HER2-positive (HER2+) breast cancer. By distribution, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and other channels. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Global Breast Cancer Market Dynamics

Drivers of the Global Breast Cancer Market

Growing Awareness and Early Detection

Increased awareness about breast cancer and the importance of early detection have led to higher participation in screening programs and routine check-ups. Government initiatives, awareness campaigns, and advocacy organizations have played a significant role in promoting early detection, contributing to market growth.

Rising Healthcare Expenditure

Increased healthcare spending, particularly in developed economies, has supported the growth of the breast cancer market. Investments in research and development, infrastructure development, and access to advanced treatment modalities have positively impacted the market.

Restraints in the Global Breast Cancer Market

Challenges in Personalized Medicine

Breast cancer is a heterogeneous disease, with different subtypes and variations in treatment response. Developing personalized treatment approaches and identifying the most suitable therapies for each patient can be challenging and time-consuming, limiting widespread adoption of precision medicine.

Healthcare Inequalities and Access to Care

Disparities in healthcare access, particularly in low-income regions and underserved populations, pose a significant restraint. Limited access to screening programs, diagnostic facilities, specialized treatments, and supportive care services can hinder timely diagnosis and optimal treatment, impacting market growth.

Market Trends of the Global Breast Cancer Key

Rise of Targeted Therapies: Targeted therapies have revolutionized breast cancer treatment by selectively targeting specific molecular abnormalities in cancer cells. HER2-targeted therapies, such as monoclonal antibodies and tyrosine kinase inhibitors, have significantly improved outcomes in HER2-positive breast cancer. Additionally, emerging targeted therapies that focus on other molecular targets, such as PI3K inhibitors and CDK4/6 inhibitors, are showing promise in various breast cancer subtypes.

Patient-Centric Approaches: There is a growing emphasis on patient-centered care in the breast cancer market. Patient advocacy groups, healthcare providers, and pharmaceutical companies are working together to address the holistic needs of breast cancer patients. This includes providing supportive care services, survivorship programs, and psychosocial support to improve the quality of life for patients throughout their journey.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
Drivers
Opportunities
Restraints
Challenges
- Regulatory Landscape
- Porters Analysis
Competitive rivalry
Threat of Substitute Products
Bargaining Power of Buyers
Threat of New Entrants
Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
Political Impact
Economic Impact
Social Impact
Technical Impact
Environmental Impact
Legal Impact
Global Breast Cancer Market by Cancer
- Market Overview
- Hormone Receptor-positive (HR+) and HER2-positive (HER2+)
Global Breast Cancer Market by Distribution Channel
- Market Overview
- hospital pharmacies
- retail pharmacies
- online pharmacies
- and other channels
Global Breast Cancer Market Size by Region
- Market Overview
- North America
USA
Canada
- Europe
Germany
Spain
France
UK
Rest of Europe
- Asia Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
- Latin America
Brazil
Rest of Latin America
- Middle East & Africa (MEA)
GCC Countries
South Africa
Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
By Development
By Company
By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Pfizer Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Novartis AG - Switzerland
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Roche Holding AG - Switzerland
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- AstraZeneca PLC - UK
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Johnson & Johnson - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Merck & Co., Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Bristol Myers Squibb Company - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Eli Lilly and Company - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Sanofi - France
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- AbbVie Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Daiichi Sankyo Company, Limited - Japan
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Amgen Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Genentech, Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Takeda Pharmaceutical Company Limited - Japan
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Eisai Co., Ltd. - Japan
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Mylan N.V. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Celgene Corporation - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Astellas Pharma Inc. - Japan
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Teva Pharmaceutical Industries Ltd. - Israel
Company Overview
Business Segment Overview
Financial Updates
Key Developments
- Hologic, Inc. - US
Company Overview
Business Segment Overview
Financial Updates
Key Developments